VA San Diego Healthcare System, San Diego, California.
National Center for PTSD, White River Junction, Vermont.
JAMA Psychiatry. 2019 Aug 1;76(8):791-799. doi: 10.1001/jamapsychiatry.2019.0638.
Co-occurrence of posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) is common and associated with psychiatric and functional problems. Understanding whether exposure therapy is tolerable and efficacious for treating PTSD and AUD is critical to ensure that best practice treatments are available.
To compare the efficacy of integrated (ie, targeting both PTSD and alcohol use) prolonged exposure (I-PE) therapy with present-centered integrated coping skills (I-CS) therapy, a more commonly available treatment, in reducing PTSD symptoms and alcohol use.
DESIGN, SETTING, AND PARTICIPANTS: This prospective randomized clinical trial with masked assessments considered 186 veterans seeking Veterans Affairs mental health services. A total of 119 veterans with PTSD and AUD were randomized. Data were collected from February 1, 2013, to May 31, 2017, before treatment, after treatment, and at 3- and 6-month follow-ups. Intention-to-treat analyses were performed.
Veterans underwent I-PE (Concurrent Treatment of PTSD and Substance Use Disorder Using Prolonged Exposure) or I-CS (Seeking Safety) therapy.
A priori planned outcomes were PTSD symptoms (Clinician Administered PTSD Scale for DSM-5) and percentage of heavy drinking days (Timeline Follow-Back) before treatment, after treatment, and at 3- and 6-month follow-ups.
A total of 119 veterans (mean [SD] age, 41.6 [12.6] years; 107 [89.9%] male) were randomized. Linear mixture models found that PTSD symptoms decreased in both conditions, with a significantly greater decrease for I-PE treatment compared with I-CS treatment (treatment × time interaction, -2.83; F3,233.1 = 4.92; Cohen d = 0.41; P = .002). The percentage of heavy drinking days improved in both conditions but was not statistically different between I-PE and I-CS treatment (treatment × time interaction, 1.8%; F3,209.9 = 0.18; Cohen d = 0.04; P = .91).
The I-PE arm had a greater reduction in PTSD symptoms than the I-CS arm and comparable drinking decreases. The study provides evidence that exposure therapy is more efficacious in treating PTSD than a more commonly available integrated treatment without exposure for comorbid PTSD and AUD.
ClinicalTrials.gov identifier: NCT01601067.
创伤后应激障碍(PTSD)和酒精使用障碍(AUD)共病很常见,并与精神和功能问题有关。了解暴露疗法是否能耐受和有效治疗 PTSD 和 AUD 至关重要,这能确保提供最佳的实践治疗方法。
比较综合(即针对 PTSD 和酒精使用)延长暴露(I-PE)疗法与目前更常用的以问题为中心的综合应对技能(I-CS)疗法治疗 PTSD 和 AUD 症状和酒精使用的疗效。
设计、地点和参与者:这是一项前瞻性随机临床试验,采用掩蔽评估,共纳入 186 名寻求退伍军人事务部心理健康服务的退伍军人。共有 119 名 PTSD 和 AUD 退伍军人被随机分配。数据收集于 2013 年 2 月 1 日至 2017 年 5 月 31 日,在治疗前、治疗后以及 3 个月和 6 个月随访时进行。采用意向治疗分析。
退伍军人接受 I-PE(使用延长暴露治疗 PTSD 和物质使用障碍)或 I-CS(寻求安全)治疗。
预先计划的结局是 PTSD 症状(DSM-5 临床医生管理 PTSD 量表)和大量饮酒天数(时间线随访),分别在治疗前、治疗后以及 3 个月和 6 个月随访时进行评估。
共有 119 名退伍军人(平均[标准差]年龄,41.6[12.6]岁;107[89.9%]为男性)被随机分配。线性混合模型发现,两种情况下 PTSD 症状均有所减轻,I-PE 治疗组的减轻程度明显大于 I-CS 治疗组(治疗×时间交互作用,-2.83;F3,233.1=4.92;Cohen d=0.41;P=0.002)。两种情况下大量饮酒天数均有所改善,但 I-PE 和 I-CS 治疗之间无统计学差异(治疗×时间交互作用,1.8%;F3,209.9=0.18;Cohen d=0.04;P=0.91)。
I-PE 组 PTSD 症状的减轻程度大于 I-CS 组,且饮酒量减少相当。该研究提供的证据表明,暴露疗法治疗 PTSD 的疗效优于更常用的不包含暴露治疗的综合治疗方法,后者用于治疗 PTSD 和 AUD 共病。
ClinicalTrials.gov 标识符:NCT01601067。